Loading clinical trials...
Loading clinical trials...
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China: A Nation-wide, Multi-center, Prospective, Non-interventional Study
Conditions
Interventions
Trastuzumab deruxtecan (T-DXd)
Locations
36
China
China-Japan Friendship Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Peking University First Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
Beijing GoBroad Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
Start Date
February 27, 2025
Primary Completion Date
July 31, 2027
Completion Date
July 31, 2027
Last Updated
July 8, 2025
NCT06532006
NCT05190445
NCT05982834
NCT05955833
NCT05619016
Lead Sponsor
Daiichi Sankyo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions